In the BioHarmony Drug Report Database
Siponimod
Mayzent (siponimod) is a small molecule pharmaceutical. Siponimod was first approved as Mayzent on 2019-03-26. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 4 and sphingosine 1-phosphate receptor 3. Mayzent’s patents are valid until 2030-11-30 (FDA).
Trade Name
|
Mayzent |
|---|---|
Common Name
|
siponimod |
ChEMBL ID
|
CHEMBL2336071 |
Indication
|
relapsing-remitting multiple sclerosis |
Drug Class
|
Immunomodulators |
Image (chem structure or protein)